Sarepta Therapeutics (NASDAQ:SRPT) is a biotechnology firm that specializes in the discovery and development of precision genetic medicines. The company's primary focus is on treatments for rare diseases, especially those affecting the muscular and central nervous systems. Sarepta Therapeutics is known for its groundbreaking work in Duchenne muscular dystrophy (DMD) therapies, aiming to address the underlying genetic causes of this and other diseases to improve patients' lives significantly. As of now, the company is actively involved in various stages of research, clinical trials, and the development of new drug candidates, with the objective of expanding its portfolio of therapies and making a meaningful impact in areas with unmet medical needs.